Abstract: Described herein is a 2K solvent borne coating system. The coating system includes an epoxy component (A), including: i) an epoxy resin; ii)—a solvent; iii)—at least one compound of formula (I): [(ER)x(R?O)y(HO)z(R?)t(SiO(4-x-y-z-t)]m??(I) and/or oligomer or polymer compounds of the compound of formula (I), and iv)—optionally, at least one non-catalytic additive; and an acid resin component (B), including: an carboxylic acid resin; a solvent; optionally, at least one catalyst; and optionally, at least one additive. Also described herein are a 2K coating composition, a method to coat an automotive substrate with the composition, and a scratch and mar resistant coated surface of the 2K coating composition.

Abstract: Described herein is an aqueous basecoat composition. Also described herein are a method of coating a substrate and use of the aqueous basecoat composition for improving the performance properties of basecoat materials.

Abstract: Described herein is a 2K solvent borne coating system. The coating system includes an epoxy component (A), including: i) an epoxy resin; ii) a solvent; iii) at least one compound of formula (I): [(ER)x(R?O)y(HO)z(R?)t(SiO(4-x-y-z-t)]m??(I) and/or oligomer or polymer compounds of the compound of formula (I), and iv) optionally, at least one non-catalytic additive; and an acid resin component (B), including: an carboxylic acid resin; a solvent; optionally, at least one catalyst; and optionally, at least one additive. Also described herein are a 2K coating composition, a method to coat an automotive substrate with the composition, and a scratch and mar resistant coated surface of the 2K coating composition.

Abstract: The described invention relates to sarecycline, related compounds, intermediates and salts thereof and processes for preparing the same.

Abstract: An embodiment of the invention provides an apparatus comprising: a hypervisor comprising a virtual caching appliance (VCA) and an intermediate multipathing module that interfaces with VCA; wherein the intermediate multipathing module is configured to pass an I/O request from a virtual machine to the VCA; and wherein the VCA is configured to determine if the I/O request is to be passed from the VCA to a solid state storage or if the I/O request is to be passed from the VCA to a hard disk storage. Another embodiment of the invention provides a method comprising: passing an I/O request from a virtual machine to a virtual caching appliance (VCA) in a hypervisor; and determining if the I/O request is to be passed from the VCA to a solid state storage or if the I/O request is to be passed from the VCA to a hard disk storage.

Abstract: Compounds for the treatment of sickle-cell disease, and methods for their use are provided. The compounds have a dual mode of action. First, binding of the compounds to hemoglobin increases the oxygen affinity of both normal and sickle hemoglobin. Secondly, binding of these compounds to the N-terminal amino acid of sickle hemoglobin results in destabilization of potential contacts between sickle hemoglobin molecules, preventing polymerization and the formation of fibrous precipitates of the sickle hemoglobin. The compounds are also useful for inducing hypoxia, e.g. to augment cancer treatments.

Abstract: A family of substituted chiral allosteric effectors of hemoglobin is useful for delivering more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood.

Abstract: Chemical structures have been identified which allosterically modify pyrvate kinase and either inhibit or activate enzymatic activity. These compounds can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, such as the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate.

Abstract: A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the oxygen affinity of outdated blood.

Abstract: A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the oxygen affinity of outdated blood.

Abstract: A family of compounds has been found to be useful for right-shifting hemoglobin towards a low oxygen affinity state. The compounds are capable of acting on hemoglobin in whole blood. In addition, the compounds can maintain the oxygen affinity in blood during storage and can restore the oxygen affinity of outdated blood.